Brief: Median Technologies Updates On iBiopsy's Performance

Median Technologies SA

23/11/2021 16:53

Nov 23 (Reuters) - MEDIAN TECHNOLOGIES SA  ALMDT.PA :
    * MEDIAN TECHNOLOGIES ANNOUNCES NEW OUTSTANDING PERFORMANCE
FOR
ITS IBIOPSY LUNG CANCER SCREENING CADX1 WITH A FOCUS ON STAGE 1
LUNG CANCER CHARACTERIZATION
    * IBIOPSY'S LUNG CANCER SCREENING PERFORMANCE (LCS) FOR
STAGE 1
LUNG CANCER REACHES 93.1% SENSITIVITY AT 96.2% SPECIFICITY
    * RESULTS WILL BE PRESENTED AT ANNUAL CONFERENCE OF
RADIOLOGICAL
SOCIETY OF NORTH AMERICA (RSNA, CHICAGO, IL, USA) ON NOVEMBER
28, 2021 AT 12:00 PM CT DURING AI SHOWCASE THEATER AND AT
MEDIAN'S BOOTH #4849 FROM NOV 28 TO DEC. 1 (RSNA EXHIBITION
DATES)
    * NEW RESULTS RELEASED TODAY ARE BASED ON A COHORT OF 1,737
PATIENTS FROM NATIONAL LUNG SCREENING TRIAL CASES (NLST)
CONSISTING OF A TOTAL OF 16,249 LUNG NODULES
    * TRAINING SET INCLUDED 1,239 PATIENTS WITH 11,676 NODULES
AND
TEST SET INCLUDED 498 PATIENTS HAVING A TOTAL OF 4,573 NODULES
    * THESE RESULTS ARE CRITICAL FOR LUNG CANCER
CHARACTERIZATION AT
AN EARLY STAGE, FOR WHICH IBIOPSY® DEMONSTRATES AN EXTREMELY
HIGH SPECIFICITY FOR A SENSITIVITY CLOSE TO 95%

Source text for Eikon:  ID:nBw1YX0Vra 
Further company coverage:  ALMDT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))